Acousia has raised $11.8m from backers including Boehringer Ingelheim Venture Fund to advance therapies for inner-ear impairments into the clinic.
Germany-based ear disease therapy developer Acousia Therapeutics has closed a €10m ($11.8m) series B round backed by pharmaceutical company Boehringer Ingelheim’s strategic investment unit, Boehringer Ingelheim Venture Fund (BIVF).
LBBW Venture Capital, an investment subsidiary of German state-backed banking group Landesbank Baden-Württemberg, led the round, which also featured development bank KfW, Creathor Ventures and Bregua Corporation.
Founded in 2012, Acousia Therapeutics is developing drug treatments to combat hearing loss caused by age, noise trauma or ototoxic therapy. Its approach uses…
